Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Silymarin Treatment of Pathological Gambling: A Double-Blind, Placebo-Controlled Study

NCT02337634 is registered in ClinicalTrials.gov with University of Chicago as lead sponsor.

NCT NCT02337634
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02337634 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Silymarin Treatment of Pathological Gambling: A Double-Blind, Placebo-Controlled Study
Lead sponsor
University of Chicago
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2015
Completion date
December 31, 2022
Enrollment
55 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gambling disorder, pathological gambling